@article {Bourdin1801393作者= {Arnaud布尔和唐Husereau和尼古拉斯·莫伦纳和Sarowar Golam和穆罕默德~ Kashif西迪基,莱安德罗林德纳和小许},title = {Matching-adjusted间接比较benralizumab与interleukin-5抑制剂治疗严重的哮喘:系统回顾},体积= {52}= {5},elocation-id = {1801393} = {2018}, doi ={10.1183/13993003.01393 -2018},出版商={欧洲呼吸学会},文摘= {benralizumab interleukin-5受体α-directed溶细胞的单克隆抗体,直接耗尽嗜酸性粒细胞。188bet官网地址其相对有效性与其他IL-5-targeted治疗患者严重,不受控制的哮喘是没有完全的特征。我们执行一个matching-adjusted间接比较(MAIC) benralizumab和mepolizumab reslizumab。试验选择通过系统回顾和评估的试验方法。Benralizumab患者的立场数据加权匹配treatment-effect-modifying病人的特点比较器试验之前间接效果比较。匹配的调整后,benralizumab和mepolizumab发作与安慰剂组减少了52 \ %和49 \ %,分别(率比(RR) 0.94, 95 \ % CI 0.78 {\ textendash} 1.13;n = 1524),减少需要住院治疗的急性加重率/急诊服务52 \ %和52 \ %,分别(RR 1.00, 95 \ % CI 0.57 {\ textendash} 1.75;n = 1524)。Benralizumab和mepolizumab同样改善pre-bronchodilator用力呼气量在1 s 32周(差异0.03 L, 95 \ % CI -0.06 {\ textendash} 0.12;n = 1443)。Benralizumab和reslizumab患者群体太不同的生成足够的有效样本量为MAIC产生一个可靠的估计。MAIC是一个健壮的方式间接比较治疗药效试验和异构的患者群体。 When baseline patient characteristics were matched across asthma trials, benralizumab and mepolizumab yielded similar efficacy.In an indirect treatment comparison with matched populations, benralizumab and mepolizumab had comparable efficacy http://ow.ly/e5kC30md39F}, issn = {0903-1936}, URL = {//www.qdcxjkg.com/content/52/5/1801393}, eprint = {//www.qdcxjkg.com/content/52/5/1801393.full.pdf}, journal = {European Respiratory Journal} }